BioSpace News Archive

Not every organization conducts exit interviews, but for many, they are very important procedures when an employee leaves. Learn how to successfully conduct yourself in an exit interview in our guide.

Most employers expect to receive some kind of a thank you note, either by email or handwritten, after your job interview. Yet, according to this report by talent acquisition software company iCMS, only a quarter of entry-level job applicants even bother to send a post-interview thank you message.

Changes are coming to the way 23andMe does business. The company will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported this morning.

Transthyretin Cardiomyopathy is a rare heart disease that can lead to heart failure. This weekend Pfizer presented data that shows its Phase III tafamidis therapy reduced the risk of death in patients with a distinct form of the disease by 30 percent, giving the drug the chance to become the first approved medication for these patients.

Janssen Pharmaceutical and Bayer saw the good, the bad and the potential for ugly this week with their blockbuster blood-thinner Xarelto (rivaroxaban). The drug gained approval for a new indication in Europe, failed a late-stage trial and is staring down the barrel of patent loss in 2023 while battling legal threats.

Shares of AbbVie are inching up this morning after the company announced it had secured regulatory approval for Imbruvica as a treatment for patients with a rare blood disease.

McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character.

Ann Arbor, Mich.-based Esperion Therapeutics is starting off the week with several positives. The company first reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European Society of Clinical Microbiology and Infectious Diseases (ESCMID)/American Society For Microbiology (ASM) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance to be held in Lisbon, Portugal, September 4-7, 2018.

The Alzheimer’s Research and Prevention Foundation (ARPF) announced today that Elissa Epel, Ph.D of the University of California San Francisco is giving the keynote address at their second annual Brain Longevity Therapy Training on October 12-14, 2018 in Washington, DC